血管内皮生长因子 氨酸激酶抑制剂 伦瓦提尼布治疗期间急性A型大动脉解剖
1Department of Nursing, National Taiwan University Cancer Center, Taipei, Taiwan.
Case reports in critical care
|October 9, 2025
概括
伦瓦提尼布是一种血管内皮生长因子氨酸激酶抑制剂 (VEGF-TKI),可能会增加肝细胞癌患者大动脉剖析的风险. 临床医生应在林瓦提尼布治疗期间监测心血管风险.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 血管医学 血管医学
背景情况:
- 肝细胞癌 (HCC) 是一种主要的肝癌.
- 血管内皮生长因子氨酸激酶抑制剂 (VEGF-TKI) 用于癌症治疗.
- 大动脉解剖是一种危及生命的疾病,涉及大动脉.
研究的目的:
- 报告一种急性A型大动脉剖析病例,该病例发生在接受伦瓦替尼布治疗HCC的患者中.
- 讨论VEGF-TKI治疗,特别是伦瓦提尼布和大动脉剖析之间的潜在关联.
- 提高临床医生对这种心血管风险的认识.
主要方法:
- 一个67岁的男性患有HCC,接受了伦瓦替尼的病例报告.
- 大动脉解剖的诊断通过护理点超声波和计算机断层扫描证实.
- 关于VEGF-TKI相关心血管风险的文献综述.
主要成果:
- 患者出现了严重的腹部和背部疼痛,呼吸障碍和寡尿症.
- 在住院期间诊断出A型急性大动脉剖析.
- 包括lenvatinib在内的VEGF-TKIs与大动脉剖析的低但显著风险有关.
结论:
- 伦瓦提尼布是一种VEGF-TKI,与其类中的其他药物相比,它可能具有类似或更高的大动脉解剖风险.
- 伦瓦提尼布治疗前和治疗期间,评估心血管风险至关重要.
- 临床医生必须考虑大动脉剖析在对患者的差异诊断伦瓦提尼布呈现相关症状.
相关概念视频
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
440
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
440
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
439
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
439


